Allergic bronchopulmonary aspergillosis. A review of 3 cases.
Keywords:
Aspergillus, aspergillosis, asthma, treatment, corticotherapyAbstract
Background: Allergic bronchopulmonary aspergillosis (ABPA) is a rare affection, initially described in 1952. Its pathophysiology incriminate several mecanisms in relation with the organism of the patient and the bronchial colonisation by the fongic agent.
Aim: To report three cases of ABPA.
Cases report: Three patients had been treated for ABPA in Ibn Nafiss department in Abderrahmen Mami hospital in Ariana. ABPA had been discovered in the three cases by a corticodependant asthma, refractory for different therapeutics. Positif diagnosis reposed in the 3 patients at 6 major and one minor criterion. Traitment was essentially based in corticotherapy.
Conclusion: Positif diagnosis of ABPA is actually well established, however, its traitement, although based on corticotherapy, remind not clearly codified. Association of antifongic treatment may improve the prognosis.
Downloads
References
Salez F, Lamblin C, Wallaert B. Aspergillose bronchopulmonaire allergique. Rev Mal Respir 2000; 17:265-78.
Greenberger PA, Patterson R. Allergic bronchopulmonary aspergillosis and the evaluation of patient with asthma. J allergy clin Immunol 1988; 81:646-50.
Schartz HJ, Greenberger PA. The prevalence of bronchopulmonary aspergillosis in patients with asthma, determined by serologic and radiologic criteria in patients at risk. J Lab Clin Med 1991;117:138-42.
Greenberger PA. Allergic bronchopulmonary aspergillosis. J Allergy Clin Immunol 2002;110: 685-92.
Germaud P, Renaudin K, Danner I et al. Aspergilloses bronchopulmonaires : les nouveaux enjeux. Rev Mal Respir 2001;18:257-66
Baculard A, Khiati M, Briand M et al. Aspergillose et mucoviscidose : intérêt de l'apport local d'antifongiques par lavage bronchoalvéolaire. Arch Fr Pediatr 1983 ; 40 :109-112.
Chauhan B, Santiago L, Hutcheson PS et al. Evidence for the involvement of two different MHC class II regions in susceptibility or protection in allergic broncho-pulmonary aspergillosis. J Allergy Clin Immunol 2000; 106:723-9.
Daly P, Kavanagh K.Pulmonary aspergillosis: clinical presentation, diagnosis and therapy.Br J Biomed Sci 2001;58:197-205
Ricketti AJ. Greenberger PA, Mintzer RA et al. Allergic bronchopulmonary aspergillosis. Arch Intern Med 1983; 143:1553-7.
Rosenberg M, Patterson R, Roberts M, et al. The assessement of immunologic and clinical changes occuring during corticosteroid therapy for allergic broncho-pulmonary aspergillosis. Am J Med 1978;64:599-606.
Sethi GR, Singhal KK. Pulmonary diseases and corticosteroids. Indian J Pediatr. 2008; 75:1045-56.
Grant IW. Management of allergic broncho-pulmonary aspergillosis. Respir Med 1994;88,74-75.
Salez F, Brichet A, Desurmont S et al. Effects of itraconazole therapy in allergic bronchopulmonary aspergillosis. Chest 1999; 116 :1665-8.
Mulliez P, Croxo C, Roy Saint Georges F et al. Aspergillose bronchopulmonaire allergique traitée par voriconazole. Rev Mal Respir 2006; 23:93-4
Bandres Gimeno R,Munoz Martinez MJ. Prolonged therapeutic response to voriconazole in a case of allergic bronchopulmonary aspergillosis. Arch Bronchopneumol 2007; 43:49-51.
P Germaud, A Pipet. Aspergillose bronchopulmonaire allergique : nouvelles options thérapeutiques. Rev Mal Respir 2010 ; 27 :784- 785
Randhawa I, Chin T, Nussbaum E. Resolution of corticoid-induced diabetes in allergic bronchopulmonary aspergillosis with omalizumab therapy: a novel approach J Asthma 2009; 46 : 445-447.
Germaud P, Pipet A. Points de vue sur l'aspergillose bronchopulmonaire allergique. Rev Mal Respir 2007; 24:659-61
Tillie-Leblond I, Tonnel AB. Allergic bronchopulmonary aspergillosis. Allergy 2005 ;60 :1004-13.
